Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab

Exclusion Criteria

• •Metastatic disease.
• •Surgical treatment, radiotherapy and/or previous chemotherapy.
• •Another tumour locations in head and neck area different from larynx or hypo larynx.
• •Another stages different from III or IVa without distant metastasis and resectable disease.
• •Another previous scaly carcinoma
• •Diagnosis of another neoplasia in last 5 years, except cervix carcinoma in situ and/or basocellular cutaneous carcinoma adequately treated.
• •Active infection treated by ATB IV, including active tuberculosis and VIH.
• •Hypertension not controled defined as systolic \> or = 180 mm Hg and/or diastolic \> or =130 mm Hg at rest.
• •Pregnant/lactating women.
• •Systemic immune treatment, chronic and concomitant, or cancer hormone treatment.
• •Another antineoplastics concomitant treatments.
• •Coronary artery disease or history of heart attack in the last 12 months or high risk of arrythmia uncontrolled or cardiac insufficiency uncontrolled.
• •EPOC that required more than 3 hospitalizations in the last 12 months.
• •Active ulcus not controled.
• •Psychiatric illness/social situations that would limit compliance with study requirements
• •Drug abuse (except alcohol abuse)
• •Knowledge of Allergic to study treatment.
• •Previous treatment with Monoclonal antibodies.
• •Any experimental treatment in the previous 30 days to start the study.